Jane RPh - Sutro Biopharma Chief Officer
| STRO Stock | USD 16.62 0.98 6.27% |
Insider
Jane RPh is Chief Officer of Sutro Biopharma
| Age | 55 |
| Address | 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 881 6500 |
| Web | https://www.sutrobio.com |
Sutro Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.258) % which means that it has lost $0.258 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (18.1001) %, meaning that it created substantial loss on money invested by shareholders. Sutro Biopharma's management efficiency ratios could be used to measure how well Sutro Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of January 2026, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to drop to -0.88. At this time, Sutro Biopharma's Other Current Assets are very stable compared to the past year. As of the 28th of January 2026, Debt To Assets is likely to grow to 0.12, while Total Assets are likely to drop about 304.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Heather King | Precision BioSciences | N/A | |
| Craig Muir | Pliant Therapeutics | N/A | |
| MD MBA | Pliant Therapeutics | 49 | |
| Abhinav Shukla | Shattuck Labs | ||
| Peter Hurt | InflaRx NV | N/A | |
| John Kelly | Precision BioSciences | 57 | |
| MD MBA | Shattuck Labs | 67 | |
| Evelyn RothGeissler | InflaRx NV | N/A | |
| Fatima MD | Shattuck Labs | N/A | |
| Hal MD | Pliant Therapeutics | N/A | |
| Raul Collazo | Connect Biopharma Holdings | 58 | |
| Casi DeYoung | Shattuck Labs | 55 | |
| Dean MD | Pliant Therapeutics | N/A | |
| Shane Barton | Precision BioSciences | 53 | |
| MPH MD | Connect Biopharma Holdings | 54 | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Pr MD | InflaRx NV | 56 | |
| Andrew MBA | Shattuck Labs | 40 | |
| Maria Habel | InflaRx NV | 44 | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
Management Performance
| Return On Equity | -18.1 | ||||
| Return On Asset | -0.26 |
Sutro Biopharma Leadership Team
Elected by the shareholders, the Sutro Biopharma's board of directors comprises two types of representatives: Sutro Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sutro. The board's role is to monitor Sutro Biopharma's management team and ensure that shareholders' interests are well served. Sutro Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sutro Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Leyman, Chief Officer | ||
| MBBS DPHIL, Vice Development | ||
| Shabbir Anik, Chief Technical Operations Officer | ||
| Edward Albini, CFO Sec | ||
| William JD, CEO Director | ||
| Nicki Vasquez, Chief Officer | ||
| Edward MBA, CFO Secretary | ||
| BA CPA, Chief Officer | ||
| Annie MBA, VP Relations | ||
| Venkatesh Srinivasan, Chief Officer | ||
| Anne MD, Chief Officer | ||
| Regina Cheng, Vice Controller | ||
| HansPeter Gerber, Chief Officer | ||
| Trevor Hallam, Chief Scientific Officer | ||
| ScD Swartz, Founder | ||
| MA JD, General Counsel | ||
| Jane RPh, Chief Officer | ||
| Linda Fitzpatrick, Chief Officer | ||
| Kari Leetch, Senior Culture |
Sutro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sutro Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -18.1 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.05) % | ||||
| Operating Margin | (4.01) % | ||||
| Current Valuation | (8.34 M) | ||||
| Shares Outstanding | 85.14 M | ||||
| Shares Owned By Insiders | 4.68 % | ||||
| Shares Owned By Institutions | 67.55 % | ||||
| Number Of Shares Shorted | 404.78 K | ||||
| Price To Earning | 53.08 X |
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Sutro Stock
Moving against Sutro Stock
| 0.67 | MREO | Mereo BioPharma Group | PairCorr |
| 0.58 | SLN | Silence Therapeutics PLC Downward Rally | PairCorr |
| 0.58 | PPBT | Purple Biotech | PairCorr |
| 0.56 | COEP | Coeptis Therapeutics | PairCorr |
| 0.55 | FSTF | First State Financial | PairCorr |
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sutro Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.